Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-23
2006-05-23
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S224000
Reexamination Certificate
active
07049326
ABSTRACT:
A method for modifying at least one non-ester-containing parent compound, and the compounds produced using such method, which compounds are deployed to temporarily incapacitate at least one subject are disclosed. The modified compounds are rapidly metabolized to inactive and non-toxic metabolites when exposure to the modified compounds is halted. One or more of a predetermined chemical arrangement is incorporated into the parent compound having the formula: φ-R—X—R′; where φ is a phenyl, substituted aryl or heteroaryl system present in the parent compound or is added to the parent compound; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons present in the parent compound or is added to φ; X is a carboxyl, sulfoxyl or phosphatyl function added to R; and, R′ is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons is added to X in a metabolically labile manner, or is a structural element already present as an inherent portion of the parent compound that is connected to X in a metabolically labile manner.
REFERENCES:
patent: 3150137 (1964-09-01), Buzas
patent: 3636010 (1972-01-01), Anner et al.
patent: 4093721 (1978-06-01), Phillipps et al.
patent: 4304781 (1981-12-01), Crossley
patent: 4387103 (1983-06-01), Erhardt et al.
patent: 4405642 (1983-09-01), Kam et al.
patent: 4450173 (1984-05-01), Erhardt et al.
patent: 4505926 (1985-03-01), Newsome et al.
patent: 4508725 (1985-04-01), Matier et al.
patent: 4556668 (1985-12-01), Erhardt et al.
patent: 4593119 (1986-06-01), Erhardt et al.
patent: 4604481 (1986-08-01), Kam et al.
patent: 4623652 (1986-11-01), Erhardt et al.
patent: 4692446 (1987-09-01), Erhardt et al.
patent: 4804677 (1989-02-01), Erhardt et al.
patent: 4906661 (1990-03-01), Erhardt et al.
patent: 4929623 (1990-05-01), Abe et al.
patent: 5843900 (1998-12-01), Cheronis et al.
patent: 5849788 (1998-12-01), Druzgala
patent: 6114344 (2000-09-01), Druzgala et al.
patent: 6130240 (2000-10-01), Druzgala
patent: 6159665 (2000-12-01), Chin et al.
patent: 6316487 (2001-11-01), Druzgala et al.
patent: 6362223 (2002-03-01), Druzgala et al.
patent: 6372783 (2002-04-01), Druzgala et al.
patent: 6387914 (2002-05-01), Druzgala et al.
patent: 6469064 (2002-10-01), Druzgala
patent: 2001/0056119 (2001-12-01), Druzgala et al
patent: 2002/0013330 (2002-01-01), Druzgala et al.
patent: 2002/0025970 (2002-02-01), Druzgala et al.
patent: 2002/0045620 (2002-04-01), Druzgala et al.
patent: 2002/0143002 (2002-10-01), Hochberg
patent: 2002/0169208 (2002-11-01), Druzgala
patent: 2002/0183343 (2002-12-01), Druzgala
patent: 2002/0193428 (2002-12-01), Druzgala et al.
patent: 2832310 (1980-12-01), None
patent: 0 640 601 (1995-03-01), None
patent: 0 703 910 (1996-04-01), None
patent: WO 92/14705 (1992-09-01), None
patent: WO 02/40052 (2002-05-01), None
patent: WO 02/096855 (2002-12-01), None
N. Bodor and P. Buchwald; Drug Targeting via Retrometabolic Approaches; Pharmacol. Ther. vol. 76, Nos. 1-3, pp 1-27, (1997).
R. Albrecht and O. Loge; B2—Agonists containing metabolically labile groups II. The influence of ester groups in the aryl system. Eur. J. Med.Chem-Chim Ther. 20. N 1, pp57-60 (1989).
A. Juhasz and N. Bodor; Cardiovascular studies on different classes of soft drugs; Pharmazie 55: 228-238 (2000).
M.J. Pekka Raatikainen, C. A. Napolitano, P. Druzgala and D. M. Dennis; Electrophysiological Effects of a Novel, Short-Acting and Potent Ester Derivative of Amiodarone, ATI-2001, in Guinea Pig Isolated Heart; The Journal of Pharmacology and Experimental Therapeutics; vol. 277, No. 3, pp. 1454-1463 (1996).
T. E. Morey, C. N. Seubert, M.J. Pekka Raatikainen, A. E. Martynyuk; P. Druzgala, P. Milner, M. D. Gonzalez and D. M. Dennis; Structure-Activity Relationships and Electrophysiological Effects of Short-Acting Amiodarone Homologs in Guinea Pig Isolated Heart; The Journal of Pharmacology and Experimental Therapeutics, Vo. 297, No. 1, pp. 260-266 (2001).
M.J. Pekka Raatikainen, T. E. Morey, P. Druzgala, P. Milner, M. D. Gonzalez, and D. M. Dennis; Potent and Reversible Effects of ATI-2001 on Atrial and Atrioventricular Nodal Electrophysiological Properties in Guinea Pig Isolated Perfused Heart; The Journal of Pharmacology and Experimental Therapeutics; vol. 295, No. 2, pp 779-785 (2000).
R. Albrecht and O. Loge; B2-Agonists containing metabolically labile groups. I. The influence of ester groups in the nitrogen substituent; Eur. J. Med. Chem.—Chim. Ther. 20, No., pp 51-55 (1985).
O. Rosen and F. Sandberg; Studies on N-Substituted Barbituric Acid Derivatives. II; ACTA:Chemica Scandinavica 675-687 (1950).
H.-S. Yang, W. -M. Wu and N. Bodor,Soft Drugs. XX. Design, Synthesis and Evaluation of Ultra-Short Acting beta-Blockers, Pharm. Res., 12, 329-336 (1995).
M. Graffner-Nordberg, K. Sjodin, A. Tunek and A. Halberg,Synthesis and Enzymatic Hydrolysis of Esters, Constituting Simple Models of Soft Drugs, Chem.Pharm.Bull., 46, 591-601 (1998).
R.M. Long and R.M. Weishilbourn,Recommendations of NIGMS Working Group-Understanding Individual Variations in Drug Responses: From Phenotype, NIH Reporthttp://www.hih.gov
igms
ews/reports/pharmaceogentics.html, 5 pages (Jun. 9-10, 1998).
J. Zaroslinski, R.J. Borgman, J.P. O'Donnell, W.G. Anderson, P.W. Erhardt, S.T. Kam, R.D. Reynolds, R.J. Lee and R.J. Gorczynski,Ultra-Short Acting β-Blockers: A Proposal For The Treatment of The Critically III Patient, LifeSciences, 31, 899-907 (1982).
P.W. Erhardt,Benzylamine and Dibenzylamine Revisited. Syntheses of N-Substituted Aryloxypropanolamines Exemplifying a General Route to Secondary Aliphatic Amines, Synth. Comm., 13, 103-113 (1983).
P.W. Erhardt, C.M. Woo, R.J. Gorczynski and W.G. Anderson,Ultra Short-Acting β-Adrenergic Receptor Blocking Agents. 1. (Aryloxy)propanolamines Containing Esters in the Nitrogen Substituent, J. Med. Chem., 25, 1402-1407 (1982).
P.W. Erhardt, C.M. Woo, W.G. Anderson and R.J. Gorcynski,Ultra Short-Acting β-Adrenergic Receptor Blocking Agents. 2. (Aryloxy)propanolamines Containing Esters in the Aryl Function, J. Med. Chem., 25, 1408-1412 (1982).
P.W. Erhardt, C.M. Woo, W.L. Matier, R.J. Gorcynski and W.G. Anderson,Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 3. Ethylenediamine Derivatives of(Aryloxy)propanolamines Having Esters on the Aryl Function, J. Med. Chem., 26, 1109-1112 (1983).
P.W. Erhardt,Esmolol.inChronicles of Drug Discovery, D. Lednicer, Ed. ACS Books, Washington D.C., U.S.A. 191-206 (1993).
P.W. Erhardt,A Prodrug and a Soft Drug. P.W. Erhardt, inDrug Metabolism: Databases and High-Throughput Testing During Drug Design and Development, Ed. IUPAC Books, Blackwell Science, Oxford, U.K., 62-69 (1999).
D.M. Stout, L.A. Black, CL. Barcelon-Yang, W.L. Matier, B.S. Brown, C.Y. Quon and H.F. Stampfli,Ester Derivatives of 2, 6-Bis (1-pyrrolidinylmethyl)-4-benzamidophenol as Short-Acting Antiarrhythmic Agents. 1.,J. Med. Chem.32, 1910-1913 (1989).
R.J. Chorvat, L.A. Black, V.V. Ranade, C. Barcelon-Yang, D.M. Stout, B.S. Brown, H.F. Stampfli and C.Y. QuonMono-and Bis(aminomethyl)phenylacetic Acid Esters as Short-Acting Antiarrhythmic Agents. 2.,J. Med. Chem., 36, 2494-2498 (1993).
P.W. Erhardt,Drug Metabolism Data: Past, Present, and Future Considerations, Med. Chem. Res., 8, 400-421 (1998).
P.W. Erhardt,Drug Metabolism Data: Past, Present and Future Considerations, Metabolism Databases and High Through-put Testing During Drug Design and Development, Ed. IUPAC Books, Blackwell Science, Oxford, U.K. 2-15 (1999).
P.W. Erhardt,Statistics-Based Probabilities of Metabolic Possibilities, Metabolism Databases and High Through-put Testing During Drug Design and Development, Ed. IUPAC Books, Blackwell Science, Oxford, U.K., 185-191 (1999).
P.W. Erhardt,Comparison of Commercially Available Metabolism Databases and High Through-put Testing During Drug Design and Development, Ed. IUPAC Books, Blackwell Science, Oxford, U.K., 208-222 (1999).
P. Buchwald and N. Bodor,Quantitative Structure-Metabolism Relationships: Steric and Nonsteric E
Badio Barbara P.
MacMillan Sobanski & Todd LLC
The University of Toledo
LandOfFree
Method and compositions for temporarily incapacitating subjects does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for temporarily incapacitating subjects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for temporarily incapacitating subjects will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3610880